Colorectal cancer screening - methodology

F. Jenkinson; R. J. C. Steele

doi:10.1016/j.surge.2009.10.015

Colorectal cancer screening - methodology

F. Jenkinson, R. J. C. Steele

Research output: Contribution to journal › Review article › peer-review

29 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a major problem worldwide with the highest incidence being found in developed countries, and is the 3rd most common cancer in Scotland. Patients do not generally have symptoms related to CRC until late in the disease process, so there has been much interest in developing screening programmes to detect CRC early. Most commonly, screening involves the identification of occult blood in stool samples. Alternatives include flexible sigmoidoscopy, colonoscopy, radiological investigation and the identification of DNA mutations or proteins in stool. Candidate markers for mutation identification are K-ras, BRAF, p53 and APC which may be used alone or in combination to identify those with colorectal cancer. (C) 2009 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	164-171
Number of pages	8
Journal	Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/j.surge.2009.10.015
Publication status	Published - Jun 2010

Keywords

Colorectal cancer
Screening
Faecal occult blood
DNA mutations
Fecal occult blood
Randomized controlled trial
Base-line findings
IMMUNOCHEMICAL TEST
CT Colonography
Biochip array
BRAF gene
Stool
DNA
Mutations

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.surge.2009.10.015

Cite this

@article{9b2a705dfc684ee4bcbde754df1fb307,

title = "Colorectal cancer screening - methodology",

abstract = "Colorectal cancer (CRC) is a major problem worldwide with the highest incidence being found in developed countries, and is the 3rd most common cancer in Scotland. Patients do not generally have symptoms related to CRC until late in the disease process, so there has been much interest in developing screening programmes to detect CRC early. Most commonly, screening involves the identification of occult blood in stool samples. Alternatives include flexible sigmoidoscopy, colonoscopy, radiological investigation and the identification of DNA mutations or proteins in stool. Candidate markers for mutation identification are K-ras, BRAF, p53 and APC which may be used alone or in combination to identify those with colorectal cancer. (C) 2009 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.",

keywords = "Colorectal cancer, Screening, Faecal occult blood, DNA mutations, Fecal occult blood, Randomized controlled trial, Base-line findings, IMMUNOCHEMICAL TEST, CT Colonography, Biochip array, BRAF gene, Stool, DNA, Mutations",

author = "F. Jenkinson and Steele, {R. J. C.}",

year = "2010",

month = jun,

doi = "10.1016/j.surge.2009.10.015",

language = "English",

volume = "8",

pages = "164--171",

journal = "Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland",

issn = "1479-666X",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Colorectal cancer screening - methodology

AU - Jenkinson, F.

AU - Steele, R. J. C.

PY - 2010/6

Y1 - 2010/6

N2 - Colorectal cancer (CRC) is a major problem worldwide with the highest incidence being found in developed countries, and is the 3rd most common cancer in Scotland. Patients do not generally have symptoms related to CRC until late in the disease process, so there has been much interest in developing screening programmes to detect CRC early. Most commonly, screening involves the identification of occult blood in stool samples. Alternatives include flexible sigmoidoscopy, colonoscopy, radiological investigation and the identification of DNA mutations or proteins in stool. Candidate markers for mutation identification are K-ras, BRAF, p53 and APC which may be used alone or in combination to identify those with colorectal cancer. (C) 2009 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

AB - Colorectal cancer (CRC) is a major problem worldwide with the highest incidence being found in developed countries, and is the 3rd most common cancer in Scotland. Patients do not generally have symptoms related to CRC until late in the disease process, so there has been much interest in developing screening programmes to detect CRC early. Most commonly, screening involves the identification of occult blood in stool samples. Alternatives include flexible sigmoidoscopy, colonoscopy, radiological investigation and the identification of DNA mutations or proteins in stool. Candidate markers for mutation identification are K-ras, BRAF, p53 and APC which may be used alone or in combination to identify those with colorectal cancer. (C) 2009 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

KW - Colorectal cancer

KW - Screening

KW - Faecal occult blood

KW - DNA mutations

KW - Fecal occult blood

KW - Randomized controlled trial

KW - Base-line findings

KW - IMMUNOCHEMICAL TEST

KW - CT Colonography

KW - Biochip array

KW - BRAF gene

KW - Stool

KW - DNA

KW - Mutations

U2 - 10.1016/j.surge.2009.10.015

DO - 10.1016/j.surge.2009.10.015

M3 - Review article

C2 - 20400027

SN - 1479-666X

VL - 8

SP - 164

EP - 171

JO - Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland

JF - Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland

IS - 3

ER -

Colorectal cancer screening - methodology

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this